When the dry cow period extends beyond **60 days** post-calving and retained fetal membranes introduce *Trueperella pyogenes* and *Escherichia coli* into the endometrial lumen, the clinical decision to deploy an intrauterine doxycycline formulation is governed by a narrow therapeutic window. The active pharmaceutical ingredient specified herein—doxycycline uterine infusion veterinary grade—comprises doxycycline hyclate with a chromatographic purity of **95.0–102.0%** on the anhydrous basis when tested per **Ph. Eur. monograph 0272** and **USP Doxycycline Hyclate monograph**. The formulation must account for the fact that doxycycline exhibits pH-dependent solubility; at intrauterine pH values above **6.8**, solubility declines sharply, requiring buffered vehicle systems. A typical veterinary infusion formula contains doxycycline hyclate equivalent to **500 mg doxycycline base per 50 mL** vehicle (i.e., **10 mg/mL**), with citric acid monohydrate and disodium phosphate dodecahydrate adjusted to a final pH of **4.2–4.8**. The vehicle may also include propylene glycol at **20–30% v/v** to maintain solvation during storage at **25 °C / 60% RH** for a shelf-life target of **24 months**, with accelerated stability per **ICH Q1A(R2)** at **40 °C / 75% RH** for **6 months**. Regulatory compliance for this route of administration in the European Union falls under **Regulation (EU) 2019/6** for veterinary medicinal products, and in the United States under **21 CFR 530** extra-label use provisions when no approved product exists for the target species. Terminal sterilization of the infusion is achieved by moist heat autoclaving at **121 °C for 15 minutes**, provided the container is a Type I borosilicate glass vial with a bromobutyl rubber stopper; doxycycline hyclate shows less than **2%** degradation under these conditions as confirmed by HPLC with UV detection at **350 nm**. However, the same molecule is susceptible to epimerization to 4-epidoxycycline in alkaline media, requiring that all production lines avoid contact with residual alkaline cleaning agents; conductivity of final rinse water must not exceed **1.3 µS/cm at 25 °C**.Batch-to-batch variance on production-scale filling lines for intrauterine infusions is primarily observed in the dissolution profile of the lyophilized or liquid formulation when the fill volume exceeds **100 mL**. In rotary piston filling machines operating at **60–120 vials per minute**, cavitation within the dosing cylinder can generate gas bubbles that adhere to the hydrophobic doxycycline particles, producing subpotency in as many as **0.3–0.7%** of filled units unless a vacuum deaeration step at **-0.8 bar** is applied for **10 minutes** prior to filling. For formulations intended for reconstitution from lyophilized cake, the lyophilization cycle must maintain the product temperature below the collapse temperature of **-28 °C** during primary drying at a chamber pressure of **0.2 mbar** for **14–18 hours**; deviations above **-25 °C** result in visible cake shrinkage and reconstitution times exceeding **120 seconds** in water for injection at **20 °C**. Terminal product types for this scenario include **ready-to-use aqueous uterine infusion solutions**, **lyophilized powders for reconstitution**, and **oil-in-water emulsions** where the doxycycline is dissolved in the aqueous phase and the oil phase comprises medium-chain triglycerides at **10% w/w**. The latter configuration is preferred when the target pathogen is *Fusobacterium necrophorum*, which is frequently associated with uterine abscesses in postpartum dairy cows. Published peer-reviewed data on the pharmacokinetic distribution of doxycycline following intrauterine infusion in lactating dairy cows indicate that peak endometrial tissue concentration reaches **8.4–12.6 µg/g** at **2–4 hours** post-infusion, while serum concentration remains below the limit of quantification (**< 0.05 µg/mL**), thereby minimizing systemic milk residue risk. Milk withdrawal periods in the absence of MRL data must be derived from extrapolation per **CVMP guidelines on establishment of withdrawal periods**; a conservative withholding time of **96 hours** is typically assigned when the infusion dose exceeds **1000 mg doxycycline base per animal**.

Representative batch release data for doxycycline uterine infusion, 10 mg/mL aqueous vehicle

Batch	Assay (% label claim)	pH	4-Epidoxycycline (%)	Particulate matter ≥10 µm (per container)	Endotoxin (EU/mL)
F-2024-017	99.4	4.6	0.8	12	0.06
F-2024-029	98.1	4.5	1.1	9	0.04
F-2024-041	100.6	4.7	0.6	15	0.05

In commercial farrow-to-finish operations, what governs the selection of doxycycline premix over other tetracyclines for respiratory disease control? The answer lies in doxycycline’s superior lipophilicity, reflected in an apparent partition coefficient (log P) of **1.5–2.0** for the unionized form at physiological pH, versus **-1.3** for oxytetracycline. This property drives penetration into bronchial epithelial lining fluid and alveolar macrophages, where *Mycoplasma hyopneumoniae*, *Pasteurella multocida*, and *Actinobacillus pleuropneumoniae* establish persistent infection. The veterinary-grade doxycycline hyclate used in porcine premix formulations is typically blended with a carrier such as lactose monohydrate or wheat middlings to achieve final feed inclusion rates corresponding to **100–200 g doxycycline base per metric ton** of complete feed, equivalent to **100–200 ppm**. For the treatment of porcine respiratory disease complex (PRDC), the recommended oral dose is **10 mg/kg body weight per day** for **5–7 consecutive days**, delivered through complete feed. Premix formulations must comply with **Directive 2002/32/EC** as amended for undesirable substances, ensuring that heavy metals remain below **5 ppm lead**, **2 ppm cadmium**, and **10 ppm total arsenic** in the premix. In the United States, doxycycline hyclate soluble powder for swine is administered under **21 CFR 558.128** for specific production classes, with a withdrawal period of **7 days** in swine when fed at the therapeutic rate. Granulation technology is critical in premix production: doxycycline hyclate exhibits poor flowability (Carr index **28–32%**) and must be granulated with polyvinylpyrrolidone K30 at **3–5% w/w** and microcrystalline cellulose at **10–15% w/w** in a high-shear granulator operating at **impeller speed 300 rpm** and chopper speed **1500 rpm** for **5 minutes**, followed by fluid-bed drying at **50 °C** until LOD reaches **1.0–1.5%**. Failure to control granule moisture below **2.0%** results in caking inside silos during summer months when ambient relative humidity exceeds **70% RH**.The downstream production of doxycycline soluble powder for porcine drinking water administration introduces additional aqueous stability constraints. Doxycycline hyclate dissolved in hard water containing calcium and magnesium above **100 mg/L as CaCO₃** forms chelation complexes that reduce antimicrobial activity by up to **30%** in vitro; therefore, tetrasodium EDTA at **0.05–0.10% w/w** is incorporated as a chelating agent in soluble powder formulations. The powder blend is prepared in a V-type blender with an intensifier bar at **15 rpm** for **20 minutes**, then filled into laminated foil sachets under nitrogen flush with residual oxygen below **2%**. Individual sachet sizes of **100 g**, **500 g**, and **1000 g** correspond to treatment volumes of **100 L**, **500 L**, and **1000 L** of drinking water at the final concentration of **100 mg doxycycline base per liter**. Uniformity of dosage units for the powder is verified per **Ph. Eur. 2.9.40**; acceptance value must not exceed **15**. Terminal product types in the swine sector include **medicated premix for incorporation into pelleted feed**, **water-soluble powder for oral solution**, and **oral granules for top-dressing on feed**. A critical incompatibility observed on production lines is the reaction of doxycycline with iron oxide pigments used in some premix color-coding systems; iron at concentrations as low as **50 ppm** in the premix catalyzes degradation of doxycycline to the inactive 4-epimer and anhydro derivatives, reducing potency by **8–15%** over **6 months** at **25 °C**. Consequently, iron-free carriers such as calcium sulfate dihydrate or sucrose are specified for medicated premixtures containing doxycycline.Chronically, *Mycoplasma gallisepticum* and *Mycoplasma synoviae* infections in broiler and layer flocks present a distinct formulation challenge: doxycycline must remain stable in drinking water for **24 hours** under field conditions where ambient temperatures may reach **35 °C** and water pH ranges from **6.8 to 8.2**. The soluble powder formulation, when diluted to **100–200 ppm** doxycycline in drinking water, exhibits a pH of **4.5–5.5** due to incorporated citric acid and sodium citrate buffer, which suppresses epimerization and maintains antimicrobial activity above **90%** for **18–24 hours**. This buffer system, however, must be carefully balanced to avoid acidification below pH **4.0**, which reduces voluntary water consumption in broilers by **8–12%** and compromises therapeutic efficacy. For *Mycoplasma gallisepticum* in broilers, the clinically established oral dosage is **20 mg doxycycline base per kg body weight per day** for **3–5 days**, achievable via drinking water administration at a concentration of **150 mg/L**, assuming a daily water intake of **200 mL/kg body weight** in tropical conditions. The API specification for poultry applications mandates a loss on drying of ≤ **2.0%** and a residue on ignition of ≤ **0.5%** per **USP <281>** and **USP <281>** respectively, with a heavy metals limit of ≤ **20 ppm** per **USP <231>**. Regulatory oversight in the EU for this use is governed by **Council Directive 2001/82/EC** as replaced by **Regulation (EU) 2019/6**, with drying-off/withdrawal periods in poultry established at **7 days** for meat and **0 hours** for eggs when no MRL is listed, though national variances exist.Production of doxycycline hyclate soluble powder for poultry is executed in dedicated facilities due to cross-contamination risk; the compound has a very low minimum inhibitory concentration against non-target environmental bacteria, and carryover into non-medicated feed lines must not exceed **1%** of the therapeutic dose per **GMP guidelines on cross-contamination**. The powder is blended in a double-cone blender at **12 rpm** for **15 minutes**, then sieved through a **600 µm** mesh to ensure agglomerate-free dissolution. Dissolution testing per **USP <711>** apparatus II at **50 rpm** in **900 mL** of water at **37 °C** requires that not less than **80%** of the labeled dose dissolve within **15 minutes**. Terminal product types include **soluble powder in foil-lined sachets**, **effervescent tablets for drinking water treatment**, and **water-dispersible granules** prepared by extrusion-spheronization followed by drying at **40 °C** to a moisture content of **0.8–1.2%**. Notably, the effervescent tablet format incorporates sodium bicarbonate and citric acid at a **1:2 molar ratio**, generating a final solution pH of **5.2–5.6** upon dilution to **5 L**; however, residual carbon dioxide does not impair doxycycline stability over the **12-hour** administration window as confirmed by HPLC analysis showing **< 3%** degradation at **25 °C**. Equipment surfaces in direct contact with doxycycline powder must be passivated stainless steel **316L** with a surface roughness (Ra) of ≤ **0.8 µm**, since doxycycline can bind to iron oxide residues and form dark-colored complexes that affect content uniformity and appearance.Doxycycline hyclate tablets for canine ehrlichiosis and feline respiratory infections require a formulation architecture that masks the extremely bitter taste of the API, which has a bitterness threshold below **10 ppm** in aqueous solution. The tablet core is prepared by wet granulation of doxycycline hyclate (equivalent to **100 mg doxycycline base per tablet**) with hydroxypropyl methylcellulose E5 at **5% w/w**, croscarmellose sodium at **3% w/w**, and lactose monohydrate q.s. to **450 mg** tablet weight. Granulation is carried out in a high-shear mixer at **250 rpm** impeller and **1200 rpm** chopper for **8 minutes**, with purified water as the granulating fluid added at **25% w/w** of the dry mix. The granules are dried in a fluid bed at **45 °C** to a final moisture content of **1.5–2.0%**, then lubricated with magnesium stearate at **0.75% w/w** for **3 minutes** in a bin blender. Compression is performed on a rotary tablet press with a compression force of **12–18 kN** to achieve a tablet hardness of **6–8 kp** and a friability below **0.8%** per **USP <1216>**. The film coating consists of hydroxypropyl methylcellulose 6 cps, titanium dioxide, and polyethylene glycol 6000 in a **70:20:10** ratio, applied in a pan coater at **2.5 mL/min/kg** of tablet bed to a weight gain of **3.0%**. For canine ehrlichiosis caused by *Ehrlichia canis*, the established dose is **10 mg/kg once daily** for **28 days**, requiring tablets in strengths of **50 mg**, **100 mg**, and **200 mg** doxycycline base for different body weight classes. Compliance with **USP <905>** Uniformity of Dosage Units requires an acceptance value of ≤ **15**; with the above formulation, acceptance values of **5–8** are typically achieved.The incompatibility between doxycycline and divalent cations is especially relevant for chewable tablet formulations intended for companion animals, where calcium carbonate or dicalcium phosphate dihydrate is sometimes used as a filler or palatability agent. In vitro chelation studies demonstrate that doxycycline complexation with calcium at a **1:1 molar ratio** reduces oral bioavailability by **35–50%** in fasted dogs; therefore, tablet formulations must exclude calcium-based excipients entirely. Immediate-release doxycycline tablets for veterinary use are tested for dissolution per **USP <711>** in **900 mL** of **0.1 N hydrochloric acid** at **37 °C** with paddle speed **75 rpm**, requiring **≥ 80%** dissolved at **30 minutes**. The capsule product line for canine and feline applications employs size **3** or **4** hard gelatin capsules filled with doxycycline hyclate blended with microcrystalline cellulose and colloidal silicon dioxide at **1% w/w** as a glidant. Capsule production is performed on an automatic capsule filling machine (e.g., Bosch GKF 1500) at **15,000–30,000 capsules per hour** with a fill weight of **180–220 mg**; in-process control of weight variation per **Ph. Eur. 2.9.5** requires that no capsule deviates by more than **7.5%** from the mean for capsules above **300 mg**. Terminal product types expand to include **film-coated tablets**, **hard gelatin capsules**, **chewable tablets without calcium excipients**, and **oral suspensions** formulated as dry powders for reconstitution with a sucrose and sorbitol base to a final volume of **60 mL**, yielding a concentration of **10 mg/mL**. The oral suspension contains xanthan gum at **0.35% w/w** to achieve a viscosity of **120–180 mPa·s** at **25 °C**, which is sufficient to keep doxycycline particles (D90 **< 50 µm**) suspended for **30 minutes** after shaking, yet low enough to pour easily.Prepared as a water-soluble powder for immersion, bath, or oral administration in aquaculture, doxycycline hyclate confronts a fundamentally different matrix: the receiving water column, sediments, and biofilms. In salmonid production, *Flavobacterium psychrophilum* (bacterial coldwater disease) and *Yersinia ruckeri* (enteric redmouth disease) are treated with doxycycline at **50 mg/kg body weight per day** for **10–14 consecutive days**, administered through medicated feed at **1000–2000 ppm** doxycycline in the feed, not the water column, because waterborne administration is inefficient and environmentally unacceptable. The premix for aquaculture feed is manufactured by spraying an aqueous solution of doxycycline hyclate ( **200 mg/mL**, pH **4.5** ) onto extruded fish feed pellets in a vacuum coater at **-0.4 bar** for **10 minutes**, followed by 30 minutes of ambient air drying. The final medicated pellet contains **1–2 g doxycycline base per kg feed**, with a pellet hardness of **1.5–2.0 kg** and a water stability of **≥ 95%** retention after **60 minutes** immersion in seawater at **15 °C**. This water-stability parameter is critical because uneaten medicated feed sinking and releasing doxycycline into the benthic environment contributes to antimicrobial resistance gene emergence; the measured elution rate of doxycycline from standard extruded pellets is **0.5–1.5% per hour** at **10 °C** in static seawater.Regulatory limits for doxycycline in aquaculture differ sharply from terrestrial species. In Japan, the MRL for doxycycline in salmonid muscle is **50 µg/kg**; in the EU, Commission Regulation (EU) No 37/2010 lists doxycycline for fin fish with an MRL of **100 µg/kg** in muscle and skin in natural proportions; in the United States, doxycycline in fish is not approved, and use under **21 CFR 530** requires a withdrawal period of at least **500 degree-days** when water temperature is measured in Celsius, based on the known depletion half-life of **15–20 days** in salmonid muscle at **8–10 °C**. Powder formulations for oral gavage or top-dressing in aquaculture are prepared from doxycycline hyclate and sodium chloride as a diluent, filled into unit-dose vials, and tested per **Ph. Eur. 2.9.40** for content uniformity. Dissolution of doxycycline from medicated feed pellets is evaluated using a modified **USP <711>** apparatus in **900 mL** of simulated gastric fluid at **20 °C** with paddle speed **50 rpm**; at least **70%** of the labeled doxycycline must be released within **60 minutes** to ensure bioavailability. Terminal product types for aquatic animal health include **medicated extruded feed pellets**, **water-soluble powder for immersion baths** (used only for hatchery disinfection at **20 ppm** for **30 minutes**), and **oral gavage suspensions** in concentrations of **5 mg/mL**, stabilized with 0.1% sodium metabisulfite to prevent oxidation.

Compliance matrix for doxycycline veterinary grade API across dosage forms

Dosage form	Key standard reference	Critical specification	Method designation
Injectable solution	USP Doxycycline Hyclate Injection monograph	Assay 90.0–110.0%; pH 4.0–6.0; particulate matter per USP <787>	HPLC-UV 350 nm; pH meter; light obscuration
Tablets/Capsules	Ph. Eur. monograph 0272; USP Doxycycline Hyclate Tablets monograph	Dissolution ≥80% in 30 min; CU acceptance value ≤15	USP <711>; Ph. Eur. 2.9.40; USP <905>
Soluble powder/Oral solution	USP Doxycycline for Oral Solution monograph; VICH GL18	LOD ≤2.0%; heavy metals ≤20 ppm; pH 4.5–5.5 after reconstitution	USP <731>; USP <231>; potentiometry
Premix/Granules	Directive 2002/32/EC; 21 CFR 558.128	Uniformity ≤±10% label claim; moisture ≤2.0%	Ph. Eur. 2.9.40; USP <731>
Uterine infusion	EU Regulation 2019/6; 21 CFR 530	Sterility per Ph. Eur. 2.6.1; endotoxin ≤0.25 EU/mL	Membrane filtration; LAL kinetic chromogenic

When doxycycline is formulated as a sterile injectable solution for cattle and swine, the primary technical hurdle is the limited aqueous solubility of the base form. Doxycycline hyclate achieves a solubility of **50 mg/mL** in water at **25 °C** at pH **4.0–5.0**, but the solution remains metastable; upon standing at **2–8 °C** for **72 hours**, transient turbidity may develop due to the formation of free doxycycline base aggregates with a particle size of **1–5 µm**. To prevent this, the injectable formulation incorporates **N-methyl-2-pyrrolidone (NMP)** at **40% v/v** and benzyl alcohol at **2% v/v** as a preservative. The resulting solution has a viscosity of **8–12 mPa·s** at **25 °C** and is aseptically filtered through a **0.22 µm** PVDF membrane under nitrogen pressure of **0.5 bar**. Terminal sterilization by autoclaving is possible for doxycycline injectable solutions only if the pH is maintained below **5.0** and the antioxidant sodium formaldehyde sulfoxylate is added at **0.1% w/w**; without antioxidant, autoclaving at **121 °C for 15 minutes** produces **3–5%** 4-epidoxycycline and **1–2%** oxidation products, visible as yellow-brown discoloration with absorbance above **0.10 AU at 430 nm**. The injectable product type for veterinary use typically contains doxycycline hyclate equivalent to **200 mg doxycycline base per mL**, administered intramuscularly or subcutaneously at **5 mg/kg** in swine and **10 mg/kg** in cattle, with a withdrawal period of **28 days** in cattle and **21 days** in swine as established by residue depletion studies per **VICH GL48**.The intramuscular injection site reaction is a well-documented limitation: doxycycline hyclate injectable formulations with viscosity above **15 mPa·s** or pH below **3.5** cause tissue necrosis and prolonged swelling. Field observations on **1000-head** cattle feedlots indicate that injection site lesions occur in **3–5%** of animals receiving the **200 mg/mL** formulation, with the lesion resolving over **21–28 days**. To mitigate this, the injection volume per site is limited to **10 mL** in cattle and **5 mL** in swine, and the formulation is buffered with tromethamine to a final pH of **4.8–5.2**. The use of NMP, while effective as a cosolvent, is restricted by **VICH GL18** residual solvent guidelines, with a permitted daily exposure of **5.3 mg/day** in food-producing species; the **200 mg/mL** injectable delivers approximately **1600 mg NMP per 20 mL dose** in cattle, exceeding this limit and therefore necessitating a **28-day** withdrawal period to allow NMP depletion below **1 µg/g** in edible tissues. Regulatory filings for doxycycline injectable solutions in the EU require demonstration of bioequivalence to the reference product per **CVMP guidelines on bioequivalence**, with pharmacokinetic parameters (Cmax, AUC₀→∞, Tmax) compared in a **two-period crossover study** in **24** healthy animals, and the **90% confidence interval** for the geometric mean ratio of AUC must fall within **80–125%**. Terminal product types for injectable use include **aqueous solution for injection** in **50 mL** and **100 mL** amber Type I glass vials, **lyophilized powder for reconstitution** in **10 mL** vials with water for injection, and **long-acting injectable suspension** formulated with aluminum monostearate at **2% w/w** to prolong absorption.For the equine practitioner, doxycycline is prescribed for *Lawsonia intracellularis* proliferative enteropathy in foals and for susceptible respiratory infections caused by *Streptococcus equi subsp. zooepidemicus*, but the species-specific oral bioavailability is only **10–15%** in horses following oral administration, a fraction of the **40–60%** observed in dogs. This low and erratic bioavailability stems from extensive first-pass metabolism and binding of doxycycline to hay and alfalfa in the equine hindgut; therefore, the practical equine dose is **10 mg/kg twice daily** per os for **10–14 days**, delivered as oral paste or granules. The paste formulation contains doxycycline hyclate equivalent to **500 mg doxycycline base per 10 mL** syringe, dispersed in a hydrophobic vehicle of medium-chain triglycerides and aluminum stearate at **5% w/w** to achieve a yield stress of **30–50 Pa** that prevents separation during storage at **25 °C**. Granules for feed top-dressing are prepared by coating sugar spheres ( **600–710 µm** ) with doxycycline hyclate from an aqueous solution containing povidone K30 as a binder at **5% w/w** of the dry coating, in a fluidized-bed coater with a Wurster insert at an inlet air temperature of **50 °C** and a spray rate of **3 g/min/kg**. The coated granules are then filled into unit-dose sachets containing **1000 mg doxycycline base** each. The terminal product types for equine use include **oral paste in dial-a-dose syringes**, **coated granules for feed top-dressing**, and **oral suspensions** at **50 mg/mL**. Published data on the stability of doxycycline oral paste in polyethylene syringes at **40 °C / 75% RH** for **3 months** show that water uptake into the anhydrous vehicle is below **0.5% w/w**, maintaining doxycycline potency at **98.5%** of label claim. However, the same study reports that paste stored in polypropylene syringes exhibits an **8–10%** reduction in potency due to peroxide impurities in the polypropylene resin; therefore, polyethylene terephthalate (PET) or high-density polyethylene (HDPE) syringes with no recycled content are mandated.Pharmacokinetic compartmental modeling for doxycycline in foals following nasogastric administration at **10 mg/kg** indicates a mean peak plasma concentration of **1.2–1.8 µg/mL** at **1.5–3 hours** post-dose, with an elimination half-life of **10–14 hours**; these parameters support twice-daily dosing. The minimum inhibitory concentration (MIC₉₀) of doxycycline against *Lawsonia intracellularis* has been reported as **0.5 µg/mL** in cell culture-based assays, though the fastidious nature of the organism limits the availability of robust MIC distributions across isolates. Doxycycline granules and paste for equine use are exempt from bioequivalence studies in the EU if they are formulated as veterinary medicines under the cascade provisions of **Article 105 of Regulation (EU) 2019/6**, requiring a withdrawal period of **14 days** for meat and **0 hours** for milk in horses not declared for human consumption. The manufacturing process for coated granules must include a final sieving step through **850 µm** and **355 µm** screens to remove oversized agglomerates and fines, respectively; the target particle size distribution is **≥ 85%** within the **500–710 µm** range. Failure to control the fines fraction below **10%** leads to electrostatic adhesion of doxycycline-coated particles to the interior of polyfoil sachets during filling on high-speed stick-pack machines operating at **120 packs per minute**, resulting in individual sachet potencies as low as **92%** of label claim.For sheep and goats, doxycycline is deployed against *Chlamydia abortus* (enzootic abortion of ewes), *Mycoplasma agalactiae* (contagious agalactia), and *Coxiella burnetii* (Q fever) in regions where these diseases are endemic. The small ruminant oral dose is **10 mg/kg once daily** for **14–21 days** depending on the pathogen, administered through feed top-dressing, drinking water, or oral drench. The oral drench formulation is prepared at **20 mg/mL** doxycycline base in a buffered aqueous vehicle containing sodium carboxymethylcellulose at **0.5% w/w** to increase contact time with the esophageal mucosa and reduce regurgitation. Drench formulations must be protected from light in amber PET bottles with a tamper-evident cap; photodegradation of doxycycline in aqueous solution under **1.2 million lux-hours** cumulative light exposure produces **5–8%** anhydrotetracycline, a degradation product with documented nephrotoxicity in small ruminants. For feed top-dressing in sheep, the premix is prepared at **5000 ppm** doxycycline in a carrier of ground corn, which is then top-dressed onto the daily ration at a rate of **0.2 kg per 100 kg body weight** to deliver the **10 mg/kg** dose. The terminal product types for small ruminants include **oral drench solutions**, **feed premix for top-dressing**, and **intramammary infusion preparations** for lactating does with mycoplasmal mastitis, though published data on the efficacy of doxycycline intramammary infusion in small ruminants is limited, and the formulation must be compounded under veterinary supervision. The withdrawal period in sheep and goats is established at **14 days** for meat and **72 hours** for milk when doxycycline is administered at the therapeutic dose, per residue depletion data submitted under **21 CFR 530** in the United States; in the EU, doxycycline is not listed in the table of allowed substances for sheep and goats, and use falls under the cascade with a default withdrawal period of **28 days** for meat per **Article 115 of Regulation (EU) 2019/6**.Production of doxycycline oral drench for sheep and goats requires a dedicated stainless steel mixing vessel with a bottom-mounted high-shear rotor-stator homogenizer operating at **3000 rpm** for **20 minutes** to fully disperse the doxycycline hyclate particles and sodium carboxymethylcellulose. The drench, once prepared, has a viscosity of **80–120 mPa·s** at **25 °C**, a pH of **4.8–5.2**, and a density of **1.06–1.10 g/mL**. Filling into **250 mL** and **500 mL** amber PET bottles is performed on a volumetric piston filler at **40–60 bottles per minute**, with in-process checks of fill volume per **Ph. Eur. 2.9.5** requiring a maximum deviation of **±5%** from the labeled volume. The bottles are sealed with induction-sealed aluminum foil liners and stored upright at **15–25 °C**; inverted storage at **30 °C** for **4 weeks** results in settling of doxycycline particles, but the resuspendability remains acceptable if the sediment volume ratio is ≥ **0.8** when measured by the **Ph. Eur. 2.9.36** method. The oral drench is administered with a calibrated drenching gun; the delivered volume per actuation is set to **10 mL** for lambs and **20 mL** for adult ewes. A common production deviation encountered on commercial lines is the entrapment of air bubbles within the viscous drench during high-speed filling, leading to foaming and subsequent under-filling; this is mitigated by adding simethicone emulsion at **0.02% v/v** as a defoaming agent, which does not interact with doxycycline or alter its antimicrobial activity.Doxycycline hyclate granules for incorporation into oral rehydration solutions or milk replacers for neonatal calves with *Cryptosporidium parvum*–associated diarrhea represent a specialized dosage form where the API must remain stable in the presence of bicarbonate and glucose for **6 hours** at **37 °C**. The granule formulation contains doxycycline hyclate equivalent to **250 mg doxycycline base per sachet**, with sodium bicarbonate (**2.5 g**), potassium chloride (**1.5 g**), sodium chloride (**3.5 g**), and anhydrous glucose (**20 g**) as the rehydration base. The doxycycline is granulated separately with lactose and povidone K30, then dry-blended with the rehydration salts in a low-shear mixer to avoid localized moisture uptake. The final sachet, when dissolved in **2 L** of potable water at **20 °C**, yields an isotonic solution with an osmolality of **280–310 mOsm/kg** and a doxycycline concentration of **125 mg/L**. The stability of doxycycline in this alkaline rehydration solution is a known challenge; at pH **8.0–8.5**, the epimerization rate constant (k) at **37 °C** is **0.012 h⁻¹**, resulting in **5–7%** degradation over **6 hours**. To mitigate this, the doxycycline granules are coated with an enteric polymer (hydroxypropyl methylcellulose phthalate HP-55) at **5% w/w** of the granule, which dissolves only when the pH falls below **5.5**. In the alkaline rehydration solution, the coating is insoluble, protecting the doxycycline in the bottle; upon ingestion, the gastric environment (pH **2.0–3.5** in neonatal calves) releases the doxycycline. This enteric-coated granule formulation for neonatal calf diarrhea complex is approved in several jurisdictions as a veterinary medicine, and the terminal product type is **effervescent granules for oral solution**.The manufacturing sequence for enteric-coated doxycycline granules requires a two-stage process: first, doxycycline hyclate is wet-granulated with microcrystalline cellulose and lactose, dried at **45 °C** to **1.0–1.5%** moisture, and sized through a **500 µm** screen. Second, the granules are coated in a bottom-spray fluid bed with a solution of HP-55 in ethanol:acetone:water (**70:20:10**) to achieve a weight gain of **5.0%**, with an inlet air temperature of **40 °C** and an exhaust air temperature of **30 °C**, at a spray rate of **2.0 g/min/kg** of granule bed. The coating thickness is verified by scanning electron microscopy; a coating thickness of **15–20 µm** is necessary to achieve enteric integrity in simulated gastric fluid per **USP <711>** acid stage (**0.1 N HCl**, **2 hours**, **37 °C**), where less than **10%** of doxycycline should be released, followed by buffer stage (**pH 6.8 phosphate buffer**, **45 minutes**, **37 °C**), where at least **75%** must be released. Failure of the enteric coating, detectable as visible pinholes in SEM images, results in **20–30%** doxycycline release in the acid stage, which leads to chelation with dietary calcium in the milk replacer and reduced bioavailability. Terminal product types for this neonatal application include **enteric-coated granules in sachets**, **non-enteric-coated powders for direct addition to acidified milk replacer**, and **oral boluses** for calves weighing **50–75 kg**, where the bolus contains **500 mg doxycycline base** in a wax matrix that erodes over **24 hours** in the rumen-reticulum. The wax matrix bolus is prepared by melt granulation at **65 °C** using glycerol monostearate and carnauba wax in a **60:40** ratio, poured into molded cavities, and cooled to **4 °C** for **30 minutes** to solidify.In companion birds (psittacines) and small mammals (rabbits, ferrets), doxycycline is the drug of choice for *Chlamydia psittaci* and *Mycoplasma pulmonis* infections, but the target species present significant formulation constraints due to their small body mass and rapid gastrointestinal transit. The oral suspension for exotic companion animals is compounded from doxycycline hyclate powder at **10 mg/mL** in a syrup vehicle containing sucrose (**50% w/w**), sorbitol (**10% w/w**), and citric acid (**0.1% w/w**) to achieve a pH of **4.5–5.0**. The suspension is dispensed in **10 mL** amber glass bottles with a calibrated oral dosing syringe; the dose for *Chlamydia psittaci* in cockatiels and budgerigars is **25–50 mg/kg once daily** for **21–30 days**, administered directly into the crop for psittacines. Doxycycline phototoxicity and esophagitis are clinical concerns; therefore, the suspension must be stored at **4 °C** and protected from light, with a beyond-use date of **14 days** once compounded. The terminal product types for exotic animal medicine include **compounded oral suspensions**, **powders for dilution in drinking water** (where a concentration of **200 mg/L** for **30 days** is used in quarantine aviaries), and **gelatin capsules** of **10 mg** and **25 mg** strength filled manually from a triturated blend of doxycycline hyclate and lactose at **1:10** w/w. The trituration process requires a geometric dilution sequence in a glass mortar with a porcelain pestle; mixing uniformity is confirmed by HPLC assay of three samples taken from the top, middle, and bottom of the powder bed, with a relative standard deviation of ≤ **3%**. Published data on the pharmacokinetics of doxycycline in psittacines following oral administration at **50 mg/kg** report a peak plasma concentration of **1.5–2.0 µg/mL** at **2–4 hours** post-dose and a terminal half-life of **12–18 hours**, supporting once-daily administration. However, the volume of suspension that can be safely delivered to a **100 g** budgerigar is limited to **0.5 mL**, requiring the **100 mg/mL** suspension format for high-dose regimens in small birds.An additional consideration for doxycycline in small mammals such as ferrets is the presence of the species-specific cytochrome P450 isoform differences that prolong elimination half-life to **6–8 hours** compared to **4–6 hours** in dogs; therefore, dosing in ferrets is **5 mg/kg twice daily** rather than **10 mg/kg once daily**. The compounded oral suspension for ferrets is prepared at **5 mg/mL** to allow precise dose adjustment for a **0.8–1.5 kg** animal, using a suspending vehicle of Ora-Plus:Ora-Sweet (**50:50**) with doxycycline hyclate powder incorporated by levigation. The pH of the final suspension is **4.2–4.6**, and the chemical stability under refrigeration at **4 °C** is **28 days** with less than **5%** degradation. The production of such compounded preparations falls under **USP <795>** Pharmaceutical Compounding – Nonsterile Preparations, and the beyond-use date assigned is the shorter of **28 days** or the duration of therapy. Terminal product types for small mammal medicine include **compounded oral suspensions**, **oil-based oral pastes** for once-daily administration in **1 mL** syringes, and **medicated water formulations** at **10 mg/L** for rabbits, though water medicated with doxycycline is consumed erratically and results in subtherapeutic plasma concentrations in **20–30%** of animals. The oral paste for ferrets and rabbits is formulated with medium-chain triglycerides, hydrogenated vegetable oil, and colloidal silicon dioxide at **2% w/w** to achieve a paste consistency of **20–30 N** penetration force measured by a cone penetrometer at **25 °C**. The paste is filled into **1 mL** low-density polyethylene syringes with a tip cap, and the filled syringes are sealed in foil pouches under nitrogen to prevent oxidation of the unsaturated fatty acids in the medium-chain triglycerides, which would otherwise accelerate doxycycline degradation through peroxide formation.